In HER2 tumors, the anti-HER2 targeted drugs lapatinib [22] and trastuzumab [48] trigger protective autophagy to maintain the resistant phenotype [20], and accordingly, abrogation of autophagy by specific inhibitors (like chloroquine, CQ) can re-sensitize cancer cells to these drugs and enhance tumor cell death in preclinical models [20]. The gene discussed is ERBB2; the disease is neoplasm.